Review Of Emergent's $325M Smallpox Drug Deal Extended
Emergent BioSolutions Inc. has given government enforcers additional time to review its planned $325 million deal with Chimerix Inc. for the rights to Tembexa, the first antiviral approved in the U.S....To view the full article, register now.
Already a subscriber? Click here to view full article